Revisiting the isobole and related quantitative methods for assessing drug synergism - PubMed (original) (raw)

Review

Ronald J Tallarida. J Pharmacol Exp Ther. 2012 Jul.

Abstract

The isobole is well established and commonly used in the quantitative study of agonist drug combinations. This article reviews the isobole, its derivation from the concept of dose equivalence, and its usefulness in providing the predicted effect of an agonist drug combination, a topic not discussed in pharmacology textbooks. This review addresses that topic and also shows that an alternate method, called "Bliss independence," is inconsistent with the isobolar approach and also has a less clear conceptual basis. In its simplest application the isobole is the familiar linear plot in cartesian coordinates with intercepts representing the individual drug potencies. It is also shown that the isobole can be nonlinear, a fact recognized by its founder (Loewe) but neglected or rejected by virtually all other users. Whether its shape is linear or nonlinear the isobole is equally useful in detecting synergism and antagonism for drug combinations, and its theoretical basis leads to calculations of the expected effect of a drug combination. Numerous applications of isoboles in preclinical testing have shown that synergism or antagonism is not only a property of the two agonist drugs; the dose ratio is also important, a fact of potential importance to the design and testing of drug combinations in clinical trials.

PubMed Disclaimer

Figures

Fig. 1.

Fig. 1.

I, dose-effect curves for agonists with a constant potency ratio (10:1) with ED50 values of 200 and 20. II, the isobole for the 50% effect is linear, has intercepts equal to the respective ED50 values, and obeys the equation a/200 + b/20 = 1 for doses a and b. All points (a,b) on the isobole represent dose pairs that are expected to give effect = 50% _E_max when there is no interaction between the drugs. III, if the maximal effects _E_A and _E_B differ (say, _E_A = 60 and _E_B = 100), the potency ratio is not constant and the isobole, for the usual hyperbolic dose-effect curves, is nonlinear and given by the equation (Grabovsky and Tallarida, 2004):

where _C_A is the dose of drug A that gives effect ½ _E_A. For dose-effect curves with slopes that differ this result is easily generalized as discussed in Grabovsky and Tallarida (2004) and Tallarida (2006, .

Fig. 2.

Fig. 2.

Shown here is a linear isobole with an observed synergistic point P having coordinates (a,b), the additive point S with coordinates (a*,b*), and a subadditive point Q. The broken radial line denotes the dose combinations in a fixed ratio. In this case of a linear isobole the interaction index, denoted T, is calculated from the coordinates of P as T = a/A + b/B, a value less than unity and therefore indicative of synergism. For this case (linear isobole) it also follows that T is the ratio of radial distances 0P/0S, which also equals the ratio of total doses, (a + b)/(a* + b*). Situations of suspected departures from additivity require statistical testing of the difference (observed total − additive total). The variance (square of S.E.) for the additive total _Z_add is given by

The S.E. of the observed total dose is obtained from the dose-effect data of the combination. These totals and their S.E. are examined as the difference as described previously (Tallarida, 2000).

Fig. 3.

Fig. 3.

Shown is a response surface for the effect of two vasoconstrictors on isolated aortic rings, where the effect is expressed as the percentage of tension produced by KCl. Three dose combinations in the fixed ratio 94:6 were tested and showed that the two highest doses produced effects above the additive surface. Based on Lamarre and Tallarida (2008) with permission.

Similar articles

Cited by

References

    1. Adams JU, Tallarida RJ, Geller EB, Adler MW. (1993) Isobolographic superadditivity between δ and μ opioid agonists in the rat depends on the ratio of compounds, the μ agonist and the analgesic assay used. J Pharmacol Exp Ther 266:1261–1267 - PubMed
    1. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119 - PMC - PubMed
    1. Berenbaum MC. (1989) What is synergy? Pharmacol Rev 41:93–141 - PubMed
    1. Bliss CI. (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26:585–615
    1. Boehm CA, Carney EL, Tallarida RJ, Wilson RP. (2010) Midazolam enhances the analgesic properties of dexmedetomidine in the rat. Vet Anesth Analg 37:550–556 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources